Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 8(1): 2447, 2018 02 05.
Article in English | MEDLINE | ID: mdl-29402960

ABSTRACT

Mucociliary clearance is a biomechanical mechanism of airway protection. It consists of the active transport along the bronchial tree of the mucus, a fluid propelled by the coordinated beating of a myriad of cilia on the epithelial surface of the respiratory tract. The physics of mucus transport is poorly understood because it involves complex phenomena such as long-range hydrodynamic interactions, active collective ciliary motion, and the complex rheology of mucus. We propose a quantitative physical analysis of the ciliary activity and mucus transport on a large panel of human bronchial cultures from control subjects, patients with asthma and chronic obstructive pulmonary disease obtained from endobronchial biopsies. Here we report on the existence of multiple ciliary domains with sizes ranging from the tens of a micron to the centimeter, where ciliary beats present a circular orientational order. These domains are associated with circular mucus flow patterns, whose size scales with the average cilia density. In these domains, we find that the radial increase of the ciliated cell density coupled with the increase in the orientational order of ciliary beats result in a net local force proportional to the mucus velocity. We propose a phenomenological physical model that supports our results.


Subject(s)
Bronchi/ultrastructure , Cilia/ultrastructure , Mucociliary Clearance/physiology , Mucus/physiology , Respiratory Mucosa/ultrastructure , Asthma/metabolism , Asthma/physiopathology , Biomechanical Phenomena , Bronchi/metabolism , Bronchi/physiopathology , Bronchoscopy , Case-Control Studies , Cilia/metabolism , Cilia/pathology , Humans , Hydrodynamics , Models, Biological , Pulmonary Disease, Chronic Obstructive/metabolism , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Mucosa/metabolism , Respiratory Mucosa/physiopathology , Rheology , Tissue Culture Techniques
2.
Am J Respir Crit Care Med ; 188(6): 703-9, 2013 Sep 15.
Article in English | MEDLINE | ID: mdl-23947381

ABSTRACT

RATIONALE: Neutrophil serine proteases in cystic fibrosis (CF) lung secretions partially resist inhibition by natural and exogenous inhibitors, mostly because DNA impairs their control. Cationic polypeptides display the property of condensing DNA and retain antimicrobial properties. We hypothesized that DNA condensation by cationic polypeptides in CF sputum would result in a better control of CF inflammation and infection. OBJECTIVES: We examined whether poly-L-lysine would compact DNA in CF lung secretions and liquefy CF sputum, improve the control of extracellular proteases by exogenous inhibitors, and whether it displays antibacterial properties toward CF-associated bacteria. METHODS: We used fluorogenic methods to measure proteolytic activities and inhibition by protease inhibitors in whole sputum homogenates from patients with CF before and after treatment with poly-L-lysine. Antibacterial properties of poly-L-lysine were measured in bacterial cultures and in whole CF sputum. Poly-L-lysine toxicity was evaluated after aerosolization by histologic analysis, flow cytometry, and quantification of proinflammatory cytokines. MEASUREMENTS AND MAIN RESULTS: Poly-L-lysine compacts CF sputum DNA, generating a liquid phase that improves ciliary beating frequency at the lung epithelial surface, and allows the control of neutrophil elastase and cathepsin G by their natural inhibitors. It retains antimicrobial properties against Pseudomonas aeruginosa and Staphylococcus aureus at doses that induce no inflammation in the mouse lung after aerosol administration. CONCLUSIONS: Poly-L-lysine may be an alternative to dornase-α to liquefy sputum with added benefits because it helps natural inhibitors to better control the deleterious effects of extracellularly released neutrophil serine proteases and has the ability to kill bacteria in CF sputum.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cystic Fibrosis/drug therapy , DNA/drug effects , Lysine/pharmacology , Peptide Hydrolases/drug effects , Sputum/drug effects , Adult , Aged , Animals , Cathepsin G/drug effects , Cathepsin G/metabolism , Cystic Fibrosis/metabolism , DNA/metabolism , Disease Models, Animal , Female , Flow Cytometry/methods , Humans , Leukocyte Elastase/drug effects , Leukocyte Elastase/metabolism , Lung/drug effects , Lung/metabolism , Male , Mice , Middle Aged , Neutrophils/drug effects , Neutrophils/metabolism , Peptide Hydrolases/metabolism , Proteolysis/drug effects , Pseudomonas aeruginosa/drug effects , Sputum/metabolism , Staphylococcus aureus/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...